Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Markus Loeffler, Carsten Bokemeyer et al.|The Lancet Oncology|2008Cited by 1.1k
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Michael Unterhalt, Martin Dreyling et al.|Blood|2007Cited by 971
Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases<sup>§</sup>Michael Hertl, Sonja Wolff‐Franke, Detlef Zillikens et al.|JDDG Journal der Deutschen Dermatologischen Gesellschaft|2008Cited by 137
Current treatment of mantle cell lymphoma: results of a national survey and consensus meetingMathias Witzens‐Harig, M. Dreyling, J. Atta et al.|Annals of Hematology|2012Cited by 13
Empfehlungen für den Einsatz von Rituximab (anti‐CD20‐Antikörper) bei bullösen Autoimmundermatosen<sup>§</sup>Michael Hertl, Sonja Wolff‐Franke, Detlef Zillikens et al.|JDDG Journal der Deutschen Dermatologischen Gesellschaft|2008Cited by 1